



Servier steps up commitment to digital innovation for patients with Klineo partnership

Suresnes, October 16th, 2024 – Servier, an independent global pharmaceutical group, announces that it has partnered with Klineo, an innovative digital technology start-up, to improve access to and knowledge of ongoing clinical trials for patients. This partnership is an integral part of Servier's digital health strategy, reflected in [WeHealth by Servier*](#).

Access to information on clinical trials can be complex and difficult for rare disease patients and their doctors. Klineo's digital platform provides an accessible and intuitive tool that enables patients and/or referring specialists to quickly find suitable clinical trials in France. By means of a dedicated digital interface, patients can be informed in real time of therapeutic opportunities corresponding to their profile.

The aim of this partnership is to make information on currently available clinical trials more accessible, particularly in rare cancers where patient recruitment can pose a major challenge.

“Through this initial venture with Klineo, we’ll be able to validate the suitability of this particular method and consider expanding it to a larger number of studies, covering more extensive geographical areas outside France,” explains **Sophie Garnault, Director of Oncology Clinical Operations Servier**.

“Our collaboration with Klineo is a clear reflection of our commitment to putting patients at the heart of our clinical strategy and using the power of technology to deliver effective solutions and drive patient recruitment. And by making information on clinical studies more readily available, we’re helping to reduce inequalities in access to therapeutic innovations,” comments **Magali Moutte, Project Director for Servier’s WeHealth Digital Factory**.

At this point, only Servier's oncology clinical trials in France will be available on the platform. Once the initial feedback has been evaluated, the Group will consider rolling out the service to other countries.

“Our partnership with Servier will allow us to benefit from the clinical research expertise of its employees and directly support our mission to provide all patients with access to therapeutic innovations,” says **Thomas Peyresblanques, President of Klineo**.

*WeHealth by Servier is the expression of Servier's digital health strategy, aimed at two key industry players: start-ups and incubators. It is part of a dynamic, open innovation ecosystem that focuses on developing various partnerships (co-development, licensing, strategic partnerships), drawing on the expertise of our teams around the world.

Press release



Press contact

presse@servier.com

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, a source of inspiration every day.

As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria. In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine. Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.3 billion in 2023.

More information on the new Group website: servier.com

Follow us on social media: [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)

About Klineo

Founded in 2021 by a multidisciplinary team including a medical oncologist from the Institut Gustave Roussy and two engineers from the École Polytechnique, Klineo is a digital healthcare start-up whose mission is to accelerate patient inclusion in clinical trials through quick and intuitive searches. The aim is to boost the clinical development of new therapies and reduce disparities in patient access to new treatments, particularly in geographical terms.

In 2023, Klineo set up a pilot project at the Institut Gustave Roussy and launched the first national platform for triple-negative breast cancer in collaboration with a French patient association *Collectif des Triplettes Roses*. In 2024, Klineo then broadened its platform to cover all types of cancer.

Klineo also receives support from Pfizer Healthcare Hub BPI, Wilco, Onconumérique, PariSanté campus, and Unicancer, which named Klineo "Jury's Choice" in the 2022 Innovation Awards.

To find out more, visit: www.klineo.fr